comparemela.com

Hui Sheng Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DAPT noninferior to alteplase in minor nondisabling acute ischemic stroke

In patients with minor nondisabling acute ischemic stroke, treatment with dual antiplatelet therapy was noninferior to treatment with IV alteplase, according to the results of the ARAMIS trial.The researchers randomly assigned 760 patients (median age, 64 years; 31% women) with minor nondisabling acute ischemic stroke — defined as NIH Stroke Scale score of 5 or less, plus 1 point or less on

Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial | Cerebrovascular Disease | JAMA

Remote Ischemic Conditioning Neuroprotective After Stroke?

Stroke Disability Eased by Remote Ischemic Conditioning in Randomized Trial

Nonstenotic Intracranial Plaque: An Underrecognized Source of Embolic Stroke

 (adapted). High-risk, nonstenotic intracranial plaque appears to be a more important cause of embolic stroke of undetermined source (ESUS) than previously appreciated, according to findings from a Chinese imaging study. Researchers led by Lin Tao, MD (General Hospital of Northern Theater Command, Shen Yang, China), showed that this type of plaque was more common and more vulnerable on the ipsilateral versus contralateral side, differences that were not seen in patients with acute ischemic strokes related to small-vessel disease (SVD). “The present study provides the first evidence supporting an etiologic role for high-risk nonstenotic intracranial plaque in patients with ESUS,” they write, noting that “the optimal preventive strategies in these patients remain unclear.”

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.